Trial Profile
A randomized controlled trial to evaluate the effectiveness of capecitabine as a postoperative adjuvant regimen in inhibiting the recurrence of intrahepatic cholangiocarcinoma after curative resection
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 18 Jun 2013 New trial record